Ying Du Sells 50,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $32.44, for a total transaction of $1,622,000.00. Following the completion of the transaction, the chief executive officer now directly owns 494,117 shares in the company, valued at approximately $16,029,155.48. This trade represents a 9.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ying Du also recently made the following trade(s):

• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $34.47, for a total value of $1,723,500.00.

Zai Lab Price Performance

ZLAB traded up $2.27 during trading on Tuesday, reaching $34.00. 1,927,970 shares of the stock traded hands, compared to its average volume of 914,397. The stock’s 50-day simple moving average is $27.77 and its two-hundred day simple moving average is $26.06. Zai Lab Limited has a fifty-two week low of $13.48 and a fifty-two week high of $36.60. The stock has a market cap of $3.72 billion, a price-to-earnings ratio of -12.27 and a beta of 1.02.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The firm had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Research analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a research note on Wednesday, February 5th. Bank of America reaffirmed a “neutral” rating and set a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research report on Monday.

Institutional Trading of Zai Lab

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in shares of Zai Lab during the 4th quarter valued at $29,000. Pictet Asset Management Holding SA acquired a new position in Zai Lab during the fourth quarter worth $31,000. Barclays PLC raised its holdings in Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock valued at $97,000 after buying an additional 2,856 shares in the last quarter. US Bancorp DE lifted its position in shares of Zai Lab by 1,671.9% in the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock worth $154,000 after buying an additional 5,534 shares during the last quarter. Finally, Jasper Ridge Partners L.P. bought a new stake in shares of Zai Lab during the 4th quarter worth about $210,000. 41.65% of the stock is owned by institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.